Drug Search Results
More Filters [+]

Dusigitumab

Alternative Names: dusigitumab, medi-573
Latest Update: 2023-09-12
Latest Update Note: News Article

Product Description

Mechanisms of Action: IGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dusigitumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer

Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-000198-29

P2

Completed

Breast Cancer

2019-06-28

CD-ON-MEDI-573-1030

P2

Completed

Breast Cancer

2019-06-28

MEDI-573-1028

P1

Completed

Hepatocellular Carcinoma

2013-04-09

MI-CP184

P1

Completed

Oncology Solid Tumor Unspecified

2012-09-11

Recent News Events